Most Active Stocks in Pre-Market on October 21, 2025: BYND, GSIT, SPRO, TSLL, IONZ, SQQQ, NIO, F, SMR, IONQ, GM, LAC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 21 2025
0mins
Source: NASDAQ.COM
NASDAQ 100 Pre-Market Indicator: The NASDAQ 100 Pre-Market Indicator is up 11.37 points to 25,152.39, with a total pre-market volume of 257,461,702 shares traded.
Most Active Stocks: Beyond Meat (BYND) leads with 135,675,012 shares traded, currently priced at $2.19, while other notable stocks include GSI Technology (GSIT) and Spero Therapeutics (SPRO).
Stock Performance Highlights: NIO Inc. (NIO) is trading at $6.98, slightly above its target price, while Ford Motor Company (F) is set to report earnings on October 23, 2025, with a forecasted EPS increase of 49%.
Market Trends: IonQ, Inc. (IONQ) and General Motors Company (GM) have shown significant price movements, with GM up 6.54 points to $64.54, reflecting strong market activity.
Analyst Views on SPRO
Wall Street analysts forecast SPRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRO is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 2.360
Low
4.00
Averages
4.00
High
4.00
Current: 2.360
Low
4.00
Averages
4.00
High
4.00
About SPRO
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
